Eosinophilic colitis (EC) is a rare manifestation of eosinophilic gastrointestinal disorder. Even though the cut-off value of eosinophils per HPF for the diagnosis of EC is not clear, histopathological examination is still a cornerstone. Corticosteroids are the main drugs for EC treatment today. Here, we aim to report a woman with EC who showed clinical remission with budesonide and was maintained with adalimumab alone.
The burden of autoimmune diseases is rising worldwide. The expansion of the population of patients eligible for severe asthma biological therapy we are seeing in clinical practice could lead to the simultaneous use of different monoclonal antibodies. We present the case of biological combination therapy with ustekinumab and benralizumab in a patient with ulcerative colitis and severe eosinophilic asthma.
Background: We aimed to characterize the histologic gut phenotype of pediatric primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) against non-PSC colitis, and to assess Nancy Index (NI) performance in pediatric PSC-IBD.
Methods: Single-center retrospective cohort study including children diagnosed with PSC-IBD or non-PSC colitis (ulcerative colitis [UC] or IBD-unclassified) from 2000 to 2018, with diagnostic intestinal biopsies. Biopsies were re-reviewed by two independent pathologists who assessed microscopic disease distribution, NI scores, and specific histological features in the right and left colons, overall and stratified by endoscopic severity (moderate-severe vs.
We herein present four cases of Eosinophilic colitis (EoC) in adult patients who were successfully treated with a Janus kinase (JAK) inhibitor. Case 1 is a 23-year-old female who was treated with baricitinib (BAR, 4 mg, once a day) for atopic dermatitis (AD). Colonoscopy (CS) initially did not reveal any significant abnormalities.
Identifying the set of genes collectively responsible for causing a disease from differential gene expression data is called gene selection problem. Though many complex methodologies have been applied to solve gene selection, formulated as an optimization problem, this study introduces a new simple, efficient, and biologically plausible solution procedure where the collective power of the targeted gene set to discriminate between diseased and normal gene expression profiles was focused. It uses Simulated Annealing to solve the underlying optimization problem and termed here as Differential Gene Expression Based Simulated Annealing (DGESA).
IgA antibodies play a crucial role in defending against mucosal pathogens like Helicobacter pylori and Citrobacter rodentium, with strong local IgA responses observed during infections.
The study shows that production of IgA involves various immune components, including Peyer's patches and specific T-cells, and is influenced by bacterial factors like type IV secretion systems.
Interestingly, while IgA helps control H. pylori effectively, its absence leads to severe infections and weight loss with C. rodentium, highlighting that IgA's effects can vary depending on the pathogen involved.*
